Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Fludarabine + Iomab-B|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Iomab-B||I 131 MOAB BC8|131-I Apamistamab|Iodine I 131 Apamistamab||Iomab-B (131-I Apamistamab) comprises an antibody targeting CD45 conjugated to iodine 131 (I-131), which delivers I-131 to CD45-expressing cells, potentially resulting in increased death of CD45-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02665065||Phase III||Fludarabine + Iomab-B||Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)||Recruiting||USA | CAN||0|